Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
-
Published:2001-07-01
Issue:13
Volume:19
Page:3244-3254
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Sievers Eric L.1, Larson Richard A.1, Stadtmauer Edward A.1, Estey Elihu1, Löwenberg Bob1, Dombret Hervé1, Karanes Chatchada1, Theobald Matthias1, Bennett John M.1, Sherman Matthew L.1, Berger Mark S.1, Eten Catharine B.1, Loken Michael R.1, van Dongen Jacques J.M.1, Bernstein Irwin D.1, Appelbaum Frederick R.1,
Affiliation:
1. From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Pediatrics, University of Washington, and Hematologics Inc, Seattle WA; Department of Medicine, University of Chicago, Chicago, IL; Hematologic Malignancies Program, University of Pennsylvania Cancer Center, Philadelphia, PA; M.D. Anderson Cancer Center, Houston, TX; Department of Hematology, University Hospital Rotterdam, and Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands;...
Abstract
PURPOSE: Three open-label, multicenter trials were conducted to evaluate the efficacy and safety of single-agent Mylotarg (gemtuzumab ozogamicin; CMA-676; Wyeth Laboratories, Philadelphia, PA), an antibody-targeted chemotherapy agent, in patients with CD33-positive acute myeloid leukemia (AML) in untreated first relapse.PATIENTS AND METHODS: The study population comprised 142 patients with AML in first relapse with no history of an antecedent hematologic disorder and a median age of 61 years. All patients received Mylotarg as a 2-hour intravenous infusion, at a dose of 9 mg/m2, at 2-week intervals for two doses. Patients were evaluated for remission, survival, and treatment-emergent adverse events.RESULTS: Thirty percent of patients treated with Mylotarg obtained remission as characterized by 5% or less blasts in the marrow, recovery of neutrophils to at least 1,500/μL, and RBC and platelet transfusion independence. Although patients treated with Mylotarg had relatively high incidences of myelosuppression, grade 3 or 4 hyperbilirubinemia (23%), and elevated hepatic transaminase levels (17%), the incidences of grade 3 or 4 mucositis (4%) and infections (28%) were relatively low. There was a low incidence of severe nausea and vomiting (11%) and no treatment-related cardiotoxicity, cerebellar toxicity, or alopecia. Many patients received Mylotarg on an outpatient basis (38% and 41% of patients for the first and second doses, respectively). Among the 142 patients, the median total duration of hospitalization was 24 days; 16% of patients required 7 days of hospitalization or less.CONCLUSION: Administration of the antibody-targeted chemotherapy agent Mylotarg to patients with CD33-positive AML in first relapse induces complete remissions with what appears to be a favorable safety profile.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference32 articles.
1. Acute Myeloid Leukemia 2. Brincker H: Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 69: 5,1985-11, 3. Rowe JM: What is the best induction regime for acute myelogenous leukemia? Leukemia 12: S16,1998-S19, (suppl 1) 4. Bishop JF: The treatment of adult acute myeloid leukemia. Semin Oncol 24: 57,1997-69, 5. Kantarjian HM, Estey EH, Keating MA: New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10: S4,1996-S6, (suppl 1)
Cited by
750 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|